The FDA Announces Recall on Bread Sold at Walmart and Kroger in These States
This recall affects more than 880 loaves, with distribution spanning 12 states.
The recalled bread was sold at Walmart and Kroger, among other retailers.
From sandwiches to toast to croutons and more, bread is a year-round pantry staple. But before you dive into your cupboard to pull out a few slices of store-bought bread, make sure to check your loaf's packaging information. In collaboration with the Food and Drug Administration (FDA), Lewis Bake Shop recently on one of their loaves over allergen concerns.
What product has been recalled?
On July 10, 2025, Lewis Bake Shop issued a recall of their Artisan Style 1/2 Loaf, which is confirmed to have been distributed across 12 states through distributors such as Walmart and Kroger. The recall encompasses roughly 880 loaves from six different production lots.
The recall primarily affects states in the eastern Midwest and South, where the loaves were sold. Thankfully, "there have been no major reports of injury or illness to date," according to the FDA.
To identify if you have one of the recalled loaves, check the packaging for the below information:
Universal Product Code (UPC): 24126018152
Lot Codes: T10 174010206, T10 174010306, T10 174010406, T10 174020206, T10 174020306, T10 174020406
Expiration Date: 07/13/2025
What states are affected?
Alabama
Arkansas
Georgia
Illinois
Indiana
Kentucky
Michigan
Mississippi
Missouri
Ohio
Tennessee
Wisconsin
What is the exact reason for the recall?
The voluntary recall was issued after the brand realized the loaves were mislabelled. While the bread contains visible hazelnuts, the allergen was not explicitly disclosed on the packaging. There was a general allergen advisory that the product is produced on bakery equipment that may inadvertently lead to the bread containing milk or tree nuts, but hazelnuts are not specifically listed on the label. Instead of stating, "Contains Hazelnuts," the packaging read "May Contain Tree Nuts."
The company received complaints from people who saw the nuts before consuming the product. This mislabeling could result in a severe or life-threatening allergic reaction for anyone with a hazelnut allergy. Because of this, the Lewis Bake Shop decided to issue a recall out of an abundance of caution.
What to do if you have the recalled product
First, you'll want to confirm if you have one of the recalled loaves. To do this, you'll want to check the UPC, lot code and expiration date, which are located on the front and bottom of the plastic packaging. If the numbers match those detailed above, the FDA is urging customers to return the loaf to where it was purchased for a full refund.
For questions about the recall, customers can contact Hartford Bakery at 1-812-425-4642.
You Might Also Like
67 Best Gifts for Women That'll Make Her Smile
The Best Pillows for Every Type of Sleeper
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Caffeine craze warning after pouches gain in popularity with teens
While the use of caffeine pouches among teenagers remains relatively rare, experts and educators are concerned that may be about to change. Marketing aimed at teenagers of such products is spreading on social media. A school resource officer for the Boise County Sheriff's Office in Idaho, David Gomez, began noticing the use of caffeine pouches last spring, according to NBC News. The pouches can contain more than 200 milligrams of caffeine, and students have been using them along with nicotine pouches such as Zyn. Gomez noted that students would use the pouches as a disguise for nicotine pouches or they'll use both. 'They'll use the Zyn pouches that they put in their lip, and then they'll take a caffeine pouch,' said Gomez. 'They don't care what it is they're putting in their lip.' Richard Mumby is a marketing executive who was part of the launch of the e-cigarette Juul, which has been accused of initiating a wave of teen vaping. He's now back with a caffeine pouch startup known as Wip. A growing market is now trying to sell Americans on pouches as an alternative to caffeinated beverages. Mumby told NBC News that caffeine is part of 'the fabric of many Americans' everyday lives.' But he said there's room to improve. Wip and other companies are marketing caffeine pouches as a portable and affordable alternative to caffeinated drinks. It's a mix between nicotine pouches and energy drinks, placed between the lip and the gums to deliver the caffeine. Pouches, most of which do not contain nicotine, tend to last between 20 minutes and an hour, but their effect can go on for longer. Wip's flavors include mint, strawberry kiwi, and sour cherry, and each comes with 100 or 200 milligrams of caffeine, which is the same as about two cups of coffee. According to the U.S. Food and Drug Administration, that's half the amount of caffeine an adult can safely consume in an entire day. 'We take responsible caffeine consumption and responsible marketing of our product seriously,' a spokesperson for Wip told NBC News. 'While there are no legal age restrictions on caffeine products, we have adopted marketing guidelines that exceed the age-related standards set by the American Beverage Association for most common energy drinks. Wip is not intended for use by anyone under the age of 18, and our guidelines ensure the product is marketed responsibly.' Exercise and nutrition sciences professor at George Washington University's Milken Institute School of Public Health, Rob van Dam, studies caffeine. He shared concerns about the potency of some of the pouches being sold. 'It may be a bit different than coffee,' he told NBC News. 'It may hit faster, and you may overdose, in a way, more quickly.' Another worry is the possible popularity among teens, as nicotine pouches and energy drinks are already widespread. Zyn maker Philip Morris has previously told NBC News that 'Zyn's marketing is directed toward legal age nicotine users who are 21+.' The American Academy of Pediatrics has recommended that teens don't consume more than 100 milligrams of caffeine per day. The chair of the AAP's Committee on Nutrition, Dr. Mark Corkins, told NBC News that it would be better if teens avoided caffeine altogether. 'Caffeine, in general, is an area we are very concerned about,' he said. 'Pouches are just another delivery form.'
Medscape
15 minutes ago
- Medscape
Weighted Vests: Are They Effective for Weight Loss?
With the ongoing obesity epidemic, researchers are constantly looking for strategies that optimize weight loss while minimizing associated side effects. One strategy currently gaining interest is the use of weighted vests— form-fitting garments into which weights are sewn or carried in pockets, enabling the wearer to add or remove them as needed. In theory, this offers a nonpharmacologic way to induce weight loss without the side effects of medications or weight-loss surgery, but with potential bone-sparing effects. The latter is important because even modest weight loss can reduce bone density and strength, increasing the risk for fracture. Weight loss — particularly when induced by caloric restriction — is associated with bone loss, especially at the hip. This is a consequence of loss of muscle mass and an unloading of bones from the decrease in body weight. Even modest diet-induced weight loss results in small but significant reductions in hip bone mineral density (BMD), with less consistent changes at the spine or whole body. These skeletal losses may increase fracture risk, particularly in older adults, and are more pronounced when weight loss occurs in the absence of exercise. Resistance training or combined aerobic-resistance exercise mitigate but do not fully prevent this bone loss. How Do Weighted Vests Help? Weighted vests can be used to preserve muscle mass during periods of caloric restriction. This is achieved by increasing gravitational loading and placing mechanical stress on weight-bearing tissues. Local fat mass is theoretically reduced by the work required to wear the weighted vest. Preservation of muscle mass has the dual benefit of preserving bone mass and maintaining resting metabolic rate (RMR). This is important because weight loss typically results in a lower RMR, which makes subsequent weight loss more difficult. Although using weighted vests does not lead to the same degree of weight loss reported with GLP-1 receptor agonists such as semaglutide, or GLP-1/glucose-dependent insulinotropic peptide (GIP) receptor agonists such as tirzepatide, the data demonstrate benefits of this strategy. For example, 5 weeks of high-load vest use (11% of body weight worn 8 hours per day) vs a low-load vest (1% of body weight) reduced fat mass and waist circumference with no significant change in overall body weight. Loss of fat mass and a reduction in waist circumference are not inconsequential outcomes. Fat distribution (particularly an excess of visceral fat with an increased waist circumference) is a major driver of many metabolic morbidities associated with obesity. In fact, newer definitions of preclinical and clinical obesity emphasize body fat distribution and waist circumference, rather than absolute body weight. The impact of weighted vest use on skeletal health is inconclusive at this time. Snow and colleagues reported preservation of hip BMD over a 5-year period in older, postmenopausal women when weighted vest use was combined with jumping exercises. However, a randomized controlled study from Wake Forest University (INVEST in Obesity) involving 150 older adults with obesity did not find a bone-protective effect of weighted vest use or resistance training following intentional weight loss. Further studies are needed to evaluate the impact on BMD of varying durations of vest use and varying weights of the vest. In conclusion, studies thus far have not demonstrated a significant impact of weighted vests for total weight reduction, although reductions in local fat mass and waist circumference may confer some metabolic benefit. These vests may provide mechanical stimuli that support musculoskeletal integrity; however, further research is necessary to prove this point and data available thus far are conflicting.
CBS News
an hour ago
- CBS News
Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say
Pfizer CEO Albert Bourla is among those expected at a fundraiser President Trump is attending Friday at his golf club in Bedminster, New Jersey, sources told CBS News. The fundraiser for the pro-Trump super political action committee MAGA Inc. aims to raise about $25 million, one of the sources said. One day prior to the event, Mr. Trump sent letters to pharmaceutical companies, including Pfizer, demanding they lower U.S. drug prices to more evenly match what other countries pay. The White House's letters to 17 drug companies, including AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson and Sanofi, asked for commitments within 60 days to sell drugs for Medicaid patients and all new drugs at "most favored nation" rates. The president posted images of the letters to Truth Social. Mr. Trump signed an executive order in May telling federal officials to draw up "most favored nation" regulations unless pharmaceutical companies made progress toward cutting prices. This week's letters — which were addressed to Bourla and the other CEOs — accused the drugmakers of promising "more of the same" since then. The president said Friday he's "gone to war with the drug companies and, frankly, other countries" on the drug price issue. "I think we're going to be very successful fairly soon. We'll have drug prices coming down by 500, 600 800 even 1,200 percent," Mr. Trump said in an interview with Newsmax on Friday afternoon. The high cost of prescription drugs has vexed both parties for decades. Proposals to tie drug prices for U.S. patients to the typically much-lower rates charged in other developed countries have floated around for years, but the idea has faced some legal pushback. Meanwhile, drugmakers argue price caps could discourage innovation by making it harder to pay for research and development for new drugs. The industry also argues that Americans tend to have access to more groundbreaking drugs than residents of foreign countries with stricter price regulations — and says high drug prices are just one part of a broader trend of higher healthcare spending in the U.S. Bourla has engaged with Mr. Trump in the past. Pfizer was one of the drugmakers that was picked to rapidly develop COVID-19 vaccines in the first Trump administration's "Operation Warp Speed." And two weeks before Mr. Trump's second inauguration, Bourla and other Pfizer executives traveled to Mar-A-Lago for meetings, the Financial Times has previously reported. CBS News has reached out to Pfizer and the White House for comment.
